How CEOs can navigate the new era of crop input regulation

Executive summary

In crop inputs, regulation has stopped being a back-office sequence of submissions and renewals. It is now one of the variables that determines where management should commit capital, which countries deserve priority, how much risk sits inside a portfolio and whether an acquisition thesis is genuinely defensible. For boards, the practical question is no longer whether the regulatory function is busy; it is whether the company can see where regulatory uncertainty is about to change commercial options.

This report takes a CEO-level view of that shift across crop protection, biologicals and plant nutrition. The central message is deliberately pragmatic: regulatory exposure should be translated into management decisions before it becomes a compliance emergency. Companies that do this well protect enterprise value, preserve market access and create more credible options for launches, partnerships and M&A. Companies that wait until the pressure is visible in the sales forecast usually discover the issue when the response set is already narrower.

The challenge is not to predict every authority decision. No serious management team should pretend it can. The challenge is to build a decision system that can absorb uncertainty: classify products by exposure and strategic role, decide where dossier investment is justified, identify replacement or repositioning pathways early and connect regulatory timing to country, crop and channel priorities. That is the point at which regulatory affairs becomes portfolio strategy.

Why this matters now

Several structural forces are converging. Authorities are requesting more complete and locally relevant data packages. Mature active ingredients face higher scrutiny. Environmental, residue and operator-safety expectations are increasing. Biologicals and novel nutrition products may benefit from market demand, but still require clearer proof, positioning and country-specific acceptance. At the same time, distributors and growers want more certainty on label continuity, supply availability and replacement options.

These forces create a new management reality. A registration delay in one country can affect regional launch sequencing. A renewal challenge can alter the economics of a mature product family. A data gap can change whether a product should be defended, divested, partnered or replaced. A label restriction can reduce the value of a product in a specific crop system even if the registration remains formally valid. The financial effect often appears later, but the strategic decision should be made earlier.

The issue is especially important for companies operating cross-border. Crop input portfolios are rarely uniform across markets. A product may be high value in one country, marginal in another and strategically important in a third because it enables channel access or supports a broader programme. That means regulatory decisions cannot be made only at the product level. They must be made at the intersection of product, country, crop, channel and investment priority.

CEO snapshot

CEOs should ask whether the organisation has a single, decision-ready view of regulatory exposure across the portfolio. Many companies hold pieces of the answer in different functions: regulatory affairs knows authority timelines and dossier gaps; commercial teams understand country value and channel dependency; finance sees margin and working-capital impact; business development understands partner and acquisition options. The value is created when those perspectives are combined into one management view.

A useful CEO snapshot should show five things. First, which products generate material value and where. Second, which registrations or renewals are exposed to timing, data or authority risk. Third, what investment would be required to defend each product. Fourth, what alternative exists if the product becomes constrained. Fifth, what decision must be taken now rather than in six or twelve months. Without this view, leadership conversations tend to remain descriptive instead of actionable.

The most advanced companies do not wait until a renewal question emerges. They use regulatory scenario planning as part of portfolio review. They ask what happens if a key country is delayed by twelve months, if a label loses a crop, if a data package must be rebuilt, if a distributor requires replacement visibility or if a competitor benefits from a faster pathway. Those scenarios do not need to be perfect. They need to be specific enough to guide investment and risk management.

Market signals to monitor

The first signal is authority behaviour. More questions around equivalence, residues, environmental fate, operator exposure and local relevance of global data packages can indicate that a familiar pathway is becoming less predictable. Even when final approval is still likely, the cost and timing profile may change. A product that remains technically viable may become commercially weaker if timing uncertainty affects launch windows or channel confidence.

The second signal is portfolio concentration. If a high percentage of revenue depends on a small number of mature actives, older dossiers or country-specific labels, management should not wait for formal regulatory events. Concentration changes the strategic value of early defence work, alternative sourcing, replacement planning and selective acquisition. This is particularly relevant when mature products fund the development of newer platforms.

The third signal is channel sentiment. Distributors often see risk before it appears in corporate dashboards. If partners start asking about replacement plans, label stability, renewal timing or the future of a product family, the organisation should treat those questions as market intelligence. Channel concern can reduce commitment even before a regulatory outcome changes. In fragmented markets, that loss of confidence can be difficult to rebuild.

The fourth signal is competitor movement. New registrations, biological alternatives, nutrition programmes, generic pressure or local alliances can indicate that competitors are preparing for regulatory transition. A rival may not need to replace a product directly to capture value. It may simply offer the channel a more certain path at the right moment.

Portfolio decision framework

A practical portfolio framework should classify each relevant product into one of four management logics: defend, replace, reposition or exit. This classification should not be based only on regulatory feasibility. It should combine expected revenue, margin, country relevance, crop fit, data ownership, authority risk, channel dependency and the strategic role of the product within the broader offer.

Products to defend are those where regulatory investment protects meaningful enterprise value. They may be high-margin products, products that anchor distributor relationships, products that enable a broader programme or products with limited near-term substitutes. Defence requires early dossier planning, clear ownership of data gaps, authority engagement where appropriate and explicit commercial alignment on why the investment is justified.

Products to replace are those where the risk-adjusted cost of defence is too high or where long-term relevance is declining. Replacement does not mean immediate withdrawal. It means starting the search for alternative products, formulations, biological complements, partners or acquisition targets before the current product loses momentum. Replacement planning is most valuable when there is still time to manage channel transition.

Products to reposition are those that may remain viable but need a narrower or different commercial role. A label may still support certain crops, geographies or use patterns even if the original ambition no longer holds. Repositioning can preserve value if management is willing to redesign the proposition rather than defend the historical plan. This requires close collaboration between regulatory affairs, product management and sales leadership.

Products to exit are those where investment no longer makes strategic sense. Exit decisions are often delayed because the product still generates revenue. But if the margin is fragile, the data burden is high, regulatory uncertainty is increasing and strategic relevance is low, delay can destroy management focus. A disciplined exit frees resources for more defensible growth platforms.

Implications for M&A and partnerships

Regulatory exposure should be central to M&A screening and commercial diligence. A target may show attractive sales, but the buyer must understand whether those sales depend on registrations that are transferable, renewable and defensible. The diligence question is not only whether the current portfolio is registered. It is whether the registrations can sustain the investment case under realistic regulatory scenarios.

For buyers, the key diligence areas include ownership and quality of data, renewal calendar, country-by-country label strength, authority history, pending questions, local representation, supplier dependencies and the strategic value of each registration. For sellers, the same issues should be prepared before market approach. A clean regulatory narrative can reduce buyer uncertainty and protect valuation.

Partnerships are also affected. A company seeking distribution partners in high-growth regions must be able to explain regulatory timing and product continuity. A partner considering technical or commercial commitment will discount the opportunity if the regulatory pathway is unclear. Conversely, strong regulatory planning can become a source of negotiation strength, especially when competitors offer less certainty.

Management agenda

The first action is to build a regulatory heat map. This should be a board-ready view, not a technical inventory. It should rank countries and products by enterprise value, exposure, decision urgency and available alternatives. The output should make clear where management should invest, where it should monitor, where it should accelerate replacement and where it should stop spending.

The second action is to define renewal and defence gates. Before committing material dossier investment, the organisation should define what evidence is required, what commercial value is protected, what timing risk is acceptable and what fallback option exists. This prevents regulatory expenditure from becoming automatic and helps prioritise scarce technical and financial resources.

The third action is to connect regulatory planning to the annual strategy cycle. Portfolio reviews should include regulatory scenarios. Country plans should include approval timing and label-risk assumptions. M&A screening should include registration quality. Commercial launch plans should include authority and dossier milestones. This integration is what turns regulatory intelligence into management advantage.

The fourth action is to create decision ownership. Regulatory affairs should not be left alone to carry enterprise-level trade-offs. The CEO, commercial leadership, finance, product management and corporate development should agree how decisions will be made when value, risk and timing collide. Without governance, the organisation will tend to defer decisions until external events force them.

Operating model requirements

Turning regulatory pressure into strategy requires a different operating model. Many organisations still manage regulatory work through country requests, product files and reactive authority responses. That operating model can be effective for execution, but it is not sufficient for enterprise-level decision making. The CEO needs a governance model that connects regulatory affairs, commercial leadership, finance, supply, portfolio management and corporate development around shared choices.

The first requirement is a common vocabulary for value and risk. Regulatory teams may describe a product in terms of data gaps, dossier completeness and authority pathways. Commercial teams may describe the same product in terms of revenue, distributor commitment and crop opportunity. Finance may see working capital, margin and investment burden. Strategy may see optionality, partner leverage and M&A relevance. The organisation needs one translation layer that allows these functions to compare choices.

The second requirement is disciplined cadence. A regulatory portfolio review should not happen only when an authority question arrives. It should be built into the annual strategy cycle, quarterly performance reviews and major capital decisions. The agenda should include products under renewal, products with known data gaps, products exposed to regulatory pressure, products requiring label evolution and products with potential replacement pathways. The purpose is to decide what to do, not only to report status.

The third requirement is decision escalation. Some regulatory questions are technical and should remain within the expert function. Others have enterprise consequences and should be escalated quickly. A delayed registration in a priority country, a renewal risk for a high-margin product, a data ownership dispute, or a label restriction affecting a strategic crop should trigger executive review. Clear escalation rules prevent important issues from staying buried in functional workflows until the commercial impact is unavoidable.

Scenario planning and financial translation

Scenario planning is only useful if it changes management behaviour. A company does not need a complex theoretical model for every product. It needs a practical view of what happens under a small number of plausible scenarios. For example: base case approval, twelve-month delay, additional data request, label restriction, loss of a crop, or accelerated competitor approval. Each scenario should be translated into revenue timing, margin impact, working-capital implications, channel confidence and strategic response.

The financial translation is essential. Regulatory risk often appears qualitative until it is converted into cash-flow timing, investment requirement and probability-weighted value. A product with attractive sales may be less valuable if defending it requires material new data, if the authority timeline is uncertain, or if the label could narrow in a high-value crop. Conversely, a smaller product may deserve investment if it protects a distributor relationship, supports a broader programme or creates access to a strategic country.

Leadership teams should avoid false precision. The goal is not to calculate a perfect probability for every regulatory outcome. The goal is to understand the decisions that remain robust under different outcomes. If a product should be defended even under a delayed scenario, the company can move with confidence. If a product only makes sense under the most optimistic pathway, management should question whether capital is better deployed elsewhere. Scenario planning becomes valuable when it exposes these decision thresholds.

Questions for the executive committee

Which products would materially affect our growth plan if registration timing changed by twelve months? Which mature actives are funding future growth but carry rising defence risk? Which countries deserve regulatory investment because they protect strategic channel access rather than only direct revenue? Where do we need replacement options before distributors ask for them?

Which dossiers would not withstand a more demanding authority review without additional work? Which labels are commercially fragile even if formally valid? Which acquisition targets or partners could reduce exposure to a constrained product family? Which products should we stop defending because management attention is better deployed elsewhere?

These questions are not only for regulatory teams. They belong in the executive committee because they shape capital allocation, growth ambition, portfolio resilience and transaction strategy. The companies that answer them early will not eliminate uncertainty, but they will control more of the response.

Dextra perspective

Dextra's view is that the next regulatory cycle will reward companies that make regulatory uncertainty discussable in commercial terms. The useful output is not a thicker compliance pack. It is a management view that tells leadership where value is exposed, where evidence is missing, where the channel needs reassurance and where a product should no longer receive automatic investment.

In practice, that means building a roadmap with named decisions: priority products, exposed countries, required dossier work, replacement pathways, partner implications, M&A watchlist and decision dates. The roadmap will not remove uncertainty. It will make the uncertainty governable, which is what boards and executive committees need.

For CEOs, the immediate move is to change the question asked of the organisation. Ask not only what has been submitted, but which growth assumptions depend on regulatory continuity. Ask not only whether a dossier can be defended, but whether defending it is the best use of capital. Ask not only where approvals are delayed, but where delay changes channel confidence, partner leverage or deal value.

The most useful first wave is deliberately narrow: select the ten product-country-crop combinations with the highest value at risk, assign a decision owner to each and define the evidence required in the next ninety days. That exercise usually reveals where the organisation has real visibility, where it is relying on habit and where executive intervention can still create options.